United States Viral Vector Manufacturing Market to hit US$ 1.14 Billion by 2031| North America leads with 40% share | Top Companies - Sanofi SA, Thermo Fisher Scientific Inc., Cobra Biologics Ltd

Leander, Texas and Tokyo, Japan - Feb.03.2026
As per DataM intelligence research report "Viral Vector Manufacturing Market reached USD 0.9 billion in 2022 and is expected to reach USD 3.8 billion by 2031 growing with a CAGR of 20.3% during the forecast period 2024-2031."

Growth is fueled by rising gene therapy and vaccine development. Adeno-associated virus (AAV) and lentivirus vectors dominate adoption. Biopharmaceutical companies and research institutes are primary end-users. Expanding R&D pipelines, regulatory approvals, and increasing investments in personalized medicine drive market expansion.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/viral-vector-manufacturing-market?prasad
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Viral Vector Manufacturing Market: Competitive Intelligence
Sanofi SA, Thermo Fisher Scientific Inc., Cobra Biologics Ltd, Lonza Group Ltd, Merck & Co.

The Viral Vector Manufacturing Market is being significantly strengthened by Sanofi SA, Thermo Fisher Scientific Inc., Cobra Biologics Ltd, Lonza Group Ltd, and Merck & Co., as these companies collectively advance the production, scalability, and reliability of viral vectors for gene therapies and vaccines. Their technologies enable high-quality, consistent, and regulatory-compliant manufacturing of viral vectors, supporting critical applications in immunotherapy, rare disease treatment, and advanced vaccine development. By providing integrated solutions that combine bioprocessing, quality control, and scale-up capabilities, these companies contribute to the growth, stability, and technological evolution of the Viral Vector Manufacturing Market, meeting increasing global demand for gene and cell-based therapies.

The complementary strengths of these companies create strong market momentum by combining global manufacturing scale, regulatory expertise, and innovation in bioprocessing. Thermo Fisher Scientific Inc. and Lonza Group Ltd provide robust contract development and manufacturing platforms that enable scalable production of viral vectors under stringent quality standards. Sanofi SA and Merck & Co. contribute advanced biopharmaceutical development, formulation, and clinical manufacturing capabilities, supporting high-complexity vectors for global deployment. Cobra Biologics Ltd enhances the ecosystem with specialized viral vector production services and niche bioprocessing expertise. Together, this integration accelerates commercialization, optimizes production efficiency, and reinforces competitive differentiation in the Viral Vector Manufacturing Market.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/viral-vector-manufacturing-market?prasad
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Fund Raisings

✅ January 2026 - Cobra Biologics (Europe)
Cobra Biologics raised $65 million to expand its viral vector manufacturing capacity for gene and cell therapies. The funding supports process optimization, facility expansion, and accelerated production timelines.

✅ December 2025 - Catalent, Inc. (North America)
Catalent directed $58 million toward scaling viral vector production capabilities for viral gene therapy and vaccine applications. The investment strengthens manufacturing capacity and quality control systems.

✅ November 2025 - Oxford Biomedica plc (Europe)
Oxford Biomedica invested $52 million to enhance viral vector manufacturing technologies, including lentiviral and AAV platforms. The funding focuses on improving yield, process robustness, and global supply capabilities.

Product Launches & Partnerships

✅ January 2026 - Cobra Biologics (Europe)
Cobra Biologics launched an expanded viral vector manufacturing suite supporting lentiviral and adenoviral vectors. The products target gene therapy, CAR-T, and vaccine developers needing scalable solutions.

✅ December 2025 - Catalent, Inc. (North America)
Catalent introduced new viral vector manufacturing services with automated bioreactors and enhanced quality monitoring. The launch supports rapid production for clinical trials and commercial gene therapies.

✅ October 2025 - Oxford Biomedica plc (Europe)
Oxford Biomedica unveiled advanced viral vector production technologies with improved purity and scalability. The products focus on high-demand gene therapy applications and global supply consistency.

Mergers & Acquisitions

✅ January 2026 - Cobra Biologics (Europe)
Cobra expanded its viral vector capabilities through acquisition of a European gene therapy contract manufacturing company. The move strengthens its capacity for viral vector production and technical expertise.

✅ November 2025 - Catalent, Inc. (North America)
Catalent acquired a viral vector manufacturing firm to enhance service offerings for gene therapy and vaccine developers. The acquisition accelerates scale-up and global delivery capabilities.

✅ October 2025 - Oxford Biomedica plc (Europe)
Oxford Biomedica completed a strategic acquisition of a specialty viral vector production company. The deal reinforces its leadership in lentiviral and AAV manufacturing for clinical and commercial applications.

Segment Covered in the Viral Vector Manufacturing Market:
By Type
The market is segmented into retroviral vectors 20%, adenoviral vectors 25%, adeno-associated viral (AAV) vectors 35%, and other viral vectors 20%, with AAV vectors dominating due to high safety profile, efficiency in gene delivery, and increasing use in advanced gene therapies. Adenoviral vectors are growing in vaccine development and oncology applications. Retroviral and other vectors are emerging in niche therapeutic applications. Technological advancements, rising gene therapy adoption, and R&D investments drive market growth.

By Disease
Diseases include cancer 35%, genetic disorders 30%, infectious diseases 25%, and other diseases 10%, with cancer and genetic disorders dominating due to high prevalence and increasing clinical trials involving viral vectors. Infectious diseases are growing with vaccine development initiatives. Rising disease burden, precision medicine, and advanced therapeutics drive market adoption.

By Application
Applications include gene therapy 70% and vaccinology 30%, with gene therapy dominating due to increasing approvals of viral vector-based therapies, high R&D activity, and demand for personalized medicine. Vaccinology is growing with demand for viral vector vaccines, including for infectious diseases and pandemics. Innovation, regulatory support, and clinical pipeline expansion drive adoption.

By End-User
End-users include pharmaceutical and biopharmaceutical companies 80% and research institutes 20%, with pharmaceutical companies dominating due to large-scale production capabilities, commercialization of gene therapies, and clinical trial participation. Research institutes are growing in preclinical development and vector optimization. Investment in R&D and strategic collaborations support market growth.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=viral-vector-manufacturing-market
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Regional Analysis
North America - 40% Share
North America leads with 40% share due to adoption in the U.S. and Canada. AAV vectors dominate. Gene therapy is the primary application. Pharmaceutical and biopharmaceutical companies are the key end-users. Strong R&D infrastructure, high investment in biotechnology, and regulatory support drive market growth.

Europe - 25% Share
Europe holds 25% share driven by adoption in Germany, U.K., France, and Italy. AAV and adenoviral vectors dominate. Gene therapy leads applications. Pharmaceutical companies and research institutes are key end-users. Growing clinical trials, biotechnology investments, and favorable regulatory frameworks support adoption.

Asia Pacific - 20% Share
Asia Pacific accounts for 20% share due to adoption in China, Japan, South Korea, and India. AAV and adenoviral vectors dominate. Gene therapy is primary. Pharmaceutical companies and research institutes lead end-users. Rising biotechnology investments, expanding clinical trials, and government support drive market expansion.

Latin America - 5% Share
Latin America records 5% share with adoption in Brazil, Mexico, and Argentina. AAV and retroviral vectors dominate. Gene therapy is primary. Pharmaceutical companies lead end-users. Growing biotech sector and research collaborations support adoption.

Middle East & Africa - 10% Share
Middle East & Africa hold 10% share due to adoption in UAE, Saudi Arabia, and South Africa. AAV and adenoviral vectors dominate. Gene therapy is primary. Pharmaceutical companies and research institutes lead. Expansion of biotech infrastructure and increasing R&D initiatives drive market growth.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.